NYTimes: Early Data Show Moderna’s Coronavirus Vaccine Is 94.5% Effective
With the pandemic that has affected now about 53 million patients across the world, U.S. positive cases are surging every day. The drugmaker Moderna announced a 94.5% affective coronavirus vaccine. Both Pfizer and Moderna are preparing to apply to the FDA for authorization to begin distributing vaccines within several weeks. Although public health officials feared the plausibility of distributing the vaccines due to the extensively low temperature necessary to store the vaccines, Moderna’s researchers have brought hopeful news that their vaccine can last 12 hours in room temperature conditions. For the full article, click here. For more articles about Covid-19, click here.